Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Payables: 2023-2024

Historic Payables for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $1.8 million.

  • Contineum Therapeutics' Payables fell 43.74% to $786,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 147.09%. This contributed to the annual value of $1.8 million for FY2024, which is 185.20% up from last year.
  • Per Contineum Therapeutics' latest filing, its Payables stood at $1.8 million for FY2024, which was up 185.20% from $635,000 recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Payables registered a high of $1.8 million during FY2024, and its lowest value of $635,000 during FY2023.
  • Its 2-year average for Payables is $1.2 million, with a median of $1.2 million in 2023.
  • Data for Contineum Therapeutics' Payables shows a peak YoY skyrocketed of 185.20% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Payables (Yearly) stood at $635,000 in 2023, then spiked by 185.20% to $1.8 million in 2024.